STAT5A and metabolic dysfunction-associated steatotic liver disease: In this regard, EPO stimulated lipid catabolism through the activation of JAK2/STAT5 signaling in peripheral adipose tissue and ameliorated non-alcoholic fatty liver disease via EPO/EPOR-induced STAT3 and STAT5 activation [83].